| Date | Time | Source | Headline | Symbol | Company |
| 05/31/2024 | 2:43PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/31/2024 | 2:42PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/29/2024 | 4:06PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/29/2024 | 4:05PM | Business Wire | Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/29/2024 | 8:05AM | Business Wire | Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/23/2024 | 4:05PM | Business Wire | Vir Biotechnology to Host 2024 Annual Meeting of Stockholders | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/22/2024 | 8:05AM | Business Wire | Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/21/2024 | 8:17AM | Business Wire | Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/14/2024 | 4:05PM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:VIR | Vir Biotechnology Inc |
| 05/02/2024 | 4:05PM | Business Wire | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | NASDAQ:VIR | Vir Biotechnology Inc |
| 04/30/2024 | 4:05PM | Business Wire | Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
| 04/18/2024 | 8:00AM | Business Wire | Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors | NASDAQ:VIR | Vir Biotechnology Inc |
| 04/11/2024 | 4:30PM | Business Wire | Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
| 03/05/2024 | 8:05AM | Business Wire | Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/26/2024 | 7:34PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/26/2024 | 7:32PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/26/2024 | 7:32PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/26/2024 | 7:31PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/26/2024 | 4:27PM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/26/2024 | 4:10PM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/23/2024 | 8:05AM | Business Wire | Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/22/2024 | 4:12PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/22/2024 | 4:05PM | Business Wire | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/20/2024 | 4:33PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/20/2024 | 4:30PM | Business Wire | Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/16/2024 | 6:56PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/13/2024 | 5:00PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:VIR | Vir Biotechnology Inc |
| 02/01/2024 | 4:05PM | Business Wire | Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 | NASDAQ:VIR | Vir Biotechnology Inc |
| 01/03/2024 | 2:47PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIR | Vir Biotechnology Inc |
| 12/14/2023 | 5:59AM | IH Market News | Apple Stocks Reach Record, Adobe Faces Stock Drops, Berkshire Hathaway Increases Stake in OXY, and More | NASDAQ:VIR | Vir Biotechnology Inc |